Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

BackgroundPolymorphisms in MTHFR gene influence risk and overall survival of patients with brain tumor. Global genomic DNA (gDNA) methylation profile from tumor tissues is replicated in peripheral leukocytes. This study aimed to draw a correlation between rs1801133 MTHFR variants, gDNA methylation and overall survival of patients with recurrent glioblastoma (rGBM) under perillyl alcohol (POH) treatment.MethodsgDNA from whole blood was extracted using a commercially available kit (Axygen) and quantified by spectrophotometry. Global gDNA methylation was determined by ELISA and rs1801133 polymorphism by PCR-RFLP. Statistical analysis of gDNA methylation profile and rs1801133 variants included Mann-Whitney, Kruskal-Wallis, Spearman point-biserial correlation tests (SPSS and Graphpad Prism packages; significant results for effect size higher than 0.4). Prognostic value of gDNA methylation and rs1801133 variants considered survival profiles at 25weeks of POH treatment, having the date of protocol adhesion as starting count and death as the final event.ResultsMost rGBM patients showed global gDNA hypomethylation (median=31.7%) and a significant, moderate and negative correlation between TT genotype and gDNA hypomethylation (median=13.35%; rho=-0.520; p=0.003) compared to CC variant (median=32.10%), which was not observed for CT variant (median=33.34%; rho=-0.289; p=0.06). gDNA hypermethylated phenotype (median=131.90%) exhibited significant, moderate and negative correlations between TT genotype (median=112.02%) and gDNA hypermethylation levels when compared to CC (median=132.45%; rho=-0,450; p=0.04) or CT (median=137.80%; rho=-0.518; p=0.023) variants. TT variant of rs1801133 significantly decreased gDNA methylation levels for both patient groups, when compared to CC (d values: hypomethylated=1.189; hypermethylated=0.979) or CT (d values: hypomethylated=0.597; hypermethylated=1.167) variants. Positive prognostic for rGBM patients may be assigned to gDNA hypermethylation for survivors above 25weeks of treatment (median=88weeks); and TT variant of rs1801133 regardless POH treatment length.ConclusionrGBM patients under POH-based therapy harboring hypermethylated phenotype and TT variant for rs1801133 had longer survival. Intranasal POH therapy mitigates detrimental effects of gDNA hypomethylation and improved survival of patients with rGBM harboring TT mutant variant for MTHFR rs1801133 polymorphism.Trial registrationCONEP -9681- 25,000.009267 / 2004. Registered 12th July, 2004.